[Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tay-Sachs and Sandhoff diseases (GM2 gangliosidoses) are autosomal recessive lysosomal storage diseases caused by gene mutations in HEXA and HEXB, each encoding human lysosomal β-hexosaminidase α-subunits and β-subunits, respectively. In Tay-Sachs disease, excessive accumulation of GM2 ganglioside (GM2), mainly in the central nervous system, is caused by a deficiency of the HexA isozyme (αβ heterodimer), resulting in progressive neurologic disorders. In Sandhoff disease, combined deficiencies of HexA and HexB (ββ homodimer) cause not only the accumulation of GM2 but also of oligosaccharides carrying terminal N-acetylhexosamine residues (GlcNAc-oligosaccharides), resulting in systemic manifestations including hepatosplenomegaly as well as neurologic symptoms. Hence there is little clinically effective treatment for these GM2 gangliosidoses. Recent studies on the molecular pathogenesis in Sandhoff disease patients and disease model mice have shown the involvement of microglial activation and chemokine induction in neuroinflammation and neurodegeneration in this disease. Experimental and therapeutic approaches, including recombinant enzyme replacement, have been performed using Sandhoff disease model mice, suggesting the future application of novel techniques to treat GM2 gangliosidoses (Hex deficiencies), including Sandhoff disease as well as Tay-Sachs disease. In this study, we isolated astrocytes and microglia from the neonatal brain of Sandhoff disease model mice and demonstrated abnormalities of glial cells. Moreover, we demonstrated the therapeutic effect of an intracerebroventricular administration of novel recombinant human HexA carrying a high content of M6P residue in Sandhoff disease model mice.
Department of Medicinal Biotechnology, Institute of Medicinal Resources, Graduate School of Pharmaceutical Sciences, The University of Tokushima, Tokushima, Japan. dtsuji@ph.tokushima-u.ac.jp
Daisuke
D
Tsuji
D000818:Animals; D001253:Astrocytes / Q000473:pathology; D001921:Brain / Q000378:metabolism; D018925:Chemokines / Q000378:metabolism; D004195:Disease Models, Animal; D056947:Enzyme Replacement Therapy; D020143:Gangliosidoses, GM2 / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D006801:Humans; D017628:Microglia / Q000473:pathology; D058990:Molecular Targeted Therapy; D009154:Mutation; D017527:Receptor, IGF Type 2; D011994:Recombinant Proteins / Q000008:administration & dosage; D012497:Sandhoff Disease / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D013661:Tay-Sachs Disease / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D054820:beta-Hexosaminidase alpha Chain / Q000008:administration & dosage* / Q000235:genetics*; D054821:beta-Hexosaminidase beta Chain / Q000235:genetics*
D018925:Chemokines; D017527:Receptor, IGF Type 2; D011994:Recombinant Proteins; C518253:HEXA protein, human; C513386:HEXB protein, human; D054820:beta-Hexosaminidase alpha Chain; D054821:beta-Hexosaminidase beta Chain